BusinessPhoto: Mint CompaniesIndia Revises Drug Patent Rules to Prevent Evergreening
India is overhauling its drug patent guidelines to prevent pharmaceutical companies from extending patents through minor modifications, a practice known as evergreening. New draft rules by the Controller General of Patents will require stricter proof of actual medical improvement to stop delays in generic drug availability. This change impacts India’s $60 billion pharmaceutical industry, a major global supplier of generic medicines.
Mint Companies··New Delhi




